{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:41:37Z","timestamp":1792784497292,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundamental Research Funds for the Central Universities of Lanzhou University","award":["lzujbky-2022-sp08"],"award-info":[{"award-number":["lzujbky-2022-sp08"]}],"id":[{"id":"https:\/\/ror.org\/01mkqqe32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Medical Research Improvement Project of Lanzhou University","award":["lzuyxcx-2022-154"],"award-info":[{"award-number":["lzuyxcx-2022-154"]}],"id":[{"id":"https:\/\/ror.org\/01mkqqe32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Medical Innovation and Development Project of Lanzhou University","award":["lzuyxcx-2022-141"],"award-info":[{"award-number":["lzuyxcx-2022-141"]}],"id":[{"id":"https:\/\/ror.org\/01mkqqe32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Clinical Medical Research Center of Hematological Diseases in Gansu Province","award":["21JR7RA435"],"award-info":[{"award-number":["21JR7RA435"]}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"crossref","award":["21JR11RA104"],"award-info":[{"award-number":["21JR11RA104"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360029"],"award-info":[{"award-number":["82360029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01348-8","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T08:36:34Z","timestamp":1726648594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy and immune response of BCL-2 inhibitors combined with hypomethylating agents in the treatment of acute myeloid leukemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Xiaohuan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"issue":"8","key":"1348_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):66.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"1348_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291\u20139.","journal-title":"Blood"},{"issue":"24","key":"1348_CR3","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","volume":"120","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840\u20135.","journal-title":"Blood"},{"issue":"3","key":"1348_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021;96(3):282\u201391.","journal-title":"Am J Hematol"},{"issue":"7","key":"1348_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"1348_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120974","author":"HA Knaus","year":"2018","unstructured":"Knaus HA, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.120974.","journal-title":"JCI insight"},{"issue":"1","key":"1348_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-019-02449-y","volume":"69","author":"J Waidhauser","year":"2020","unstructured":"Waidhauser J, et al. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother. 2020;69(1):147\u201357.","journal-title":"Cancer Immunol Immunother"},{"key":"1348_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943839","volume":"13","author":"D Szukiewicz","year":"2022","unstructured":"Szukiewicz D. Epigenetic regulation and T-cell responses in endometriosis - something other than autoimmunity. Front Immunol. 2022;13: 943839.","journal-title":"Front Immunol"},{"issue":"12","key":"1348_CR9","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","volume":"24","author":"R Ma","year":"2022","unstructured":"Ma R, et al. Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma. Neuro Oncol. 2022;24(12):2093\u2013106.","journal-title":"Neuro Oncol"},{"issue":"20","key":"1348_CR10","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.1158\/1078-0432.CCR-17-1201","volume":"23","author":"X Li","year":"2017","unstructured":"Li X, et al. Increased IFN\u03b3(+) T cells are responsible for the clinical responses of low-dose DNA-demethylating agent decitabine antitumor therapy. Clin Cancer Res. 2017;23(20):6031\u201343.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1348_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021;138(3):234\u201345.","journal-title":"Blood"},{"issue":"11","key":"1348_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","volume":"12","author":"LM Ludwig","year":"2021","unstructured":"Ludwig LM, et al. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021;12(11):1005.","journal-title":"Cell Death Dis"},{"issue":"10393","key":"1348_CR13","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, et al. Acute myeloid leukaemia. Lancet (London, England). 2023;401(10393):2073\u201386.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1348_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13000-019-0841-1","volume":"14","author":"JD Zhou","year":"2019","unstructured":"Zhou JD, et al. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. Diagn Pathol. 2019;14(1):68.","journal-title":"Diagn Pathol"},{"issue":"1","key":"1348_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101251","volume":"34","author":"MY Konopleva","year":"2021","unstructured":"Konopleva MY. Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax. Best Pract Res Clin Haematol. 2021;34(1): 101251.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"1348_CR16","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"issue":"10","key":"1348_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/mc.23600","volume":"62","author":"L Zong","year":"2023","unstructured":"Zong L, et al. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. Mol Carcinog. 2023;62(10):1572\u201384.","journal-title":"Mol Carcinog"},{"issue":"7","key":"1348_CR18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/cncr.34608","volume":"129","author":"E Todisco","year":"2023","unstructured":"Todisco E, et al. AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992\u20131004.","journal-title":"Cancer"},{"issue":"5","key":"1348_CR19","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5(5):1552\u201364.","journal-title":"Blood Adv"},{"issue":"4","key":"1348_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.5966\/sctm.2015-0196","volume":"5","author":"KX Hu","year":"2016","unstructured":"Hu KX, et al. A study of human leukocyte antigen mismatched cellular therapy (stem cell microtransplantation) in high-risk myelodysplastic syndrome or transformed acute myelogenous leukemia. Stem Cells Transl Med. 2016;5(4):524\u20139.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"1348_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","volume":"117","author":"M Guo","year":"2011","unstructured":"Guo M, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011;117(3):936\u201341.","journal-title":"Blood"},{"issue":"6","key":"1348_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ajh.25781","volume":"95","author":"AD Sung","year":"2020","unstructured":"Sung AD, et al. Microtransplantation in older patients with AML: a pilot study of safety, efficacy and immunologic effects. Am J Hematol. 2020;95(6):662\u201371.","journal-title":"Am J Hematol"},{"issue":"4","key":"1348_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bjh.12771","volume":"165","author":"R For\u00e9s","year":"2014","unstructured":"For\u00e9s R, et al. HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases. Br J Haematol. 2014;165(4):580\u20131.","journal-title":"Br J Haematol"},{"issue":"9","key":"1348_CR24","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021;112(9):3636\u201344.","journal-title":"Cancer Sci"},{"issue":"1","key":"1348_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.18051","volume":"197","author":"S On","year":"2022","unstructured":"On S, et al. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022;197(1):63\u201370.","journal-title":"Br J Haematol"},{"issue":"17","key":"1348_CR26","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/bloodadvances.2022007333","volume":"6","author":"IM Johnson","year":"2022","unstructured":"Johnson IM, et al. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022;6(17):5227\u201331.","journal-title":"Blood Adv"},{"key":"1348_CR27","doi-asserted-by":"publisher","first-page":"204062072098664","DOI":"10.1177\/2040620720986646","volume":"12","author":"I Aldoss","year":"2021","unstructured":"Aldoss I, Pullarkat V, Stein AS. Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol. 2021;12:2040620720986646.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"1348_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11(1):68\u201379.","journal-title":"Cancer Discov"},{"issue":"7","key":"1348_CR29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.leukres.2012.03.026","volume":"36","author":"HJ Bontkes","year":"2012","unstructured":"Bontkes HJ, et al. Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. Leuk Res. 2012;36(7):921\u201330.","journal-title":"Leuk Res"},{"issue":"8","key":"1348_CR30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3324\/haematol.2012.074823","volume":"98","author":"B Costantini","year":"2013","unstructured":"Costantini B, et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 2013;98(8):1196\u2013205.","journal-title":"Haematologica"},{"issue":"3","key":"1348_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.14","volume":"4","author":"AO Gang","year":"2014","unstructured":"Gang AO, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J. 2014;4(3): e197.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1348_CR32","first-page":"36","volume":"30","author":"R Hu","year":"2022","unstructured":"Hu R, et al. Effect of decitabine on regulatory T cells relative content in peripheral blood and bone marrow of patients with myelodysplastic syndrome\/acute myeloid leukemia. Zhongguo shi yan xue ye xue za zhi. 2022;30(1):36\u201342.","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"issue":"7","key":"1348_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.molcel.2021.01.038","volume":"81","author":"H Loo Yau","year":"2021","unstructured":"Loo Yau H, et al. DNA hypomethylating agents increase activation and cytolytic activity of CD8(+) T cells. Mol Cell. 2021;81(7):1469-83.e8.","journal-title":"Mol Cell"},{"key":"1348_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108497","volume":"104","author":"HY Wu","year":"2022","unstructured":"Wu HY, et al. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D\/NKG2DL activation pathway. Int Immunopharmacol. 2022;104: 108497.","journal-title":"Int Immunopharmacol"},{"key":"1348_CR35","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.12659\/MSM.915556","volume":"25","author":"Y Lv","year":"2019","unstructured":"Lv Y, Wang H, Liu Z. The role of regulatory B cells in patients with acute myeloid leukemia. Med Sci Monitor. 2019;25:3026\u201331.","journal-title":"Med Sci Monitor"},{"issue":"38","key":"1348_CR36","doi-asserted-by":"publisher","first-page":"40747","DOI":"10.18632\/oncotarget.5688","volume":"6","author":"MS Kim","year":"2015","unstructured":"Kim MS, et al. IL-32\u03b8 gene expression in acute myeloid leukemia suppresses TNF-\u03b1 production. Oncotarget. 2015;6(38):40747\u201361.","journal-title":"Oncotarget"},{"issue":"2","key":"1348_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.47665\/tb.38.2.055","volume":"38","author":"AK Zulpa","year":"2021","unstructured":"Zulpa AK, et al. Release of pro-inflammatory cytokines TNF-\u03b1, IFN-\u03b3 and IL-6 by Burkholderia pseudomallei- stimulated peripheral blood mononucleocytes of acute myeloid leukemia patients. Trop Biomed. 2021;38(2):180\u20135.","journal-title":"Trop Biomed"},{"key":"1348_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.647713","volume":"9","author":"X Li","year":"2021","unstructured":"Li X, et al. Low-dose decitabine augments the activation and anti-tumor immune response of IFN-\u03b3(+) CD4(+) T cells through enhancing I\u03baB\u03b1 Degradation and NF-\u03baB activation. Front Cell Dev Biol. 2021;9: 647713.","journal-title":"Front Cell Dev Biol"},{"issue":"14","key":"1348_CR39","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.3390\/cancers14143352","volume":"14","author":"D Zhigarev","year":"2022","unstructured":"Zhigarev D, et al. Lymphocyte exhaustion in AML patients and impacts of HMA\/venetoclax or intensive chemotherapy on their biology. Cancers. 2022;14(14):3352.","journal-title":"Cancers"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01348-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:19:32Z","timestamp":1726730372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01348-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01348-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"451"}}